Abstract Library

#4294 Measuring quality of life in patients receiving radionuclide therapy using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- C30) and Gastro-intestinal NET (GINET) 21

Introduction: Neuroendocrine tumours over express somatostatin receptors on the cell surface. These receptors can be targeted by radiation via Peptide Receptor Radionuclide Therapy (PRRT). NETTER 01 trial demonstrated excellent results in progression-free survival. Scottish National service commenced April 2019 at Beatson West of Scotland Cancer Centre. Service Level Agreement to submit multiple metrics including Patient Reported Outcome Measures (PROM) and Patient Reported Experience Measures (PREM). EORTC QLQ 30 and GI NET 21 validated research tools which are used to measure outcomes.

Conference:

Presenting Author: Wotherspoon I

Authors: Wotherspoon I,

Keywords: EORTC 30 QLQ with the GINET 21 module,

#4287 Challenges in access to peptide receptor radionuclide therapy (PRRT) in developing countries – Insights from patient advocacy perspective

Introduction: As patient advocates and advocacy groups emerge as pivotal players in promoting access to healthcare, we explore their role in promoting radionuclide therapy in NETs.

Conference:

Presenting Author: Dureja S

Authors: Dureja S,

Keywords: Neuroendocrine tumour, Patient Advocacy, PRRT, Theranostics, Developing countries,

#4239 Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

Introduction: There is international evidence supporting nurse-led services for people with chronic diseases in reducing hospitalisations, symptom improvement and lifestyle, and patient satisfaction. Patients with NET often have high symptoms burden and psychosocial distress in the context of indolent disease. Our centre recently implemented a (NLC) to provide complex care support for patients with NET.

Conference:

Presenting Author:

Authors: Wakelin K, Michael M, Kong G, Rogers M, Natkunarajah N,

Keywords: Nurse-led care, Multidisciplinary care, Supportive care, Symptom management, Patient support,

#4231 Analysis of AI-based clinical trial search tool usage reveals motivations of neuroendocrine tumors patients in searching for trials

Introduction: It is challenging to recruit neuroendocrine tumors (NETs) patients to clinical trials. Delays in trial recruitment are detrimental to progress in clinical research. One potential reason for delays is that many patients report not being offered trials.

Conference:

Presenting Author: Mailman J

Authors: Ralic D, Mailman J,

Keywords: AI, patient engagement, clinical research, NET, clinical trials,

#3451 Peptide Receptor Radionuclide Therapy (PRRT) and impact on quality of life in patients with neuroendocrine neoplasms: An international multi-centre study

Introduction: Neuroendocrine neoplasms (NENs) affect health-related quality of life (HRQOL) due to tumor burden, hormone-secretory symptoms, and treatment-related side effects.

Conference:

Presenting Author: Kong G

Authors: Kong G, Corsini N, Hogg A, Mercurio J, Bailey D,

Keywords: PRRT, HRQOL, Neuroendocrine neoplasm, Multi-centre study, QLQ-C30,